ArticleHaemophilia : the official journal of the World Federation of Hemophilia
Thrombin Generation in Pediatric Haemophilia A Patients on Extended Half-Life FVIII versus Non-FVIII Therapies.
Article in Haemophilia : the official journal of the World Federation of Hemophilia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe therapeutic landscape for patients with haemophilia A (PwHA) is rapidly evolving with the introduction of extended half-life FVIII (EHL-FVIII) and non-FVIII therapies that mimic FVIII, such as emicizumab (EMI). Monitoring non-factor therapies in the laboratory poses challenges; however, the thrombin generation assay (TGA) can be utilized to evaluate hemostatic capacity.
aimTo compare the endogenous thrombin potential (ETP) and peak thrombin (PT) in pediatric patients with moderate to severe haemophilia A (SHA) undergoing EHL-FVIII therapies and EMI.
methodsPlatelet-poor plasma (PPP) from PwHA on EHL-FVIII or EMI prophylaxis was tested on the calibrated automated thrombogram (CAT) using PPP low reagent.
resultsETP and PT were significantly higher in the EHL-FVIII group compared to the EMI group.
conclusionPediatric patients on EHL-FVIII prophylaxis demonstrated higher ETP in vitro using PPP compared to those on EMI prophylaxis. These findings highlight the need for further systematic investigations to explore the implications of these differences in bleed control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.